BURLINGTON, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will present at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16, 2025, at 2:15 PM EDT.

Shares of LeMaitre Vascular, Inc. (NASDAQ: LMAT - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seven research firms that are covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average

2,625 shares were exercised and sold on March 11, 2026, generating a transaction value of approximately $285,000 at a weighted average sale price of around $108.50 per share. This disposition represented 28.22% of Kamke's direct holdings prior to the transaction, reducing direct ownership to 6,677 shares.

An executive of LeMaitre Vascular reported selling 2,625 shares of the company for $285,000 on March 11, 2026. The sale represented 28.22% of Kamke's direct common stock holdings, reducing the position to 6,677 shares.

Congress Asset Management Co. boosted its stake in LeMaitre Vascular, Inc. (NASDAQ: LMAT) by 5.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 732,331 shares of the medical instruments supplier's stock after acquiring an additional 40,065 shares during the quarter. Congress Asset Management Co.

The market has been going through a visible rotation. Dividend payers have been outperforming so far this year as investors rotate from large-cap AI names into “old economy” stocks. If you own software names that depend on pricing power through expensive licensing, you need to revisit your thesis. Higher energy prices would ultimately filter through to consumer and producer prices, leaving central banks scrambling to reassess their interest rate trajectory.

Dynamic Technology Lab Private Ltd bought a new stake in shares of LeMaitre Vascular, Inc. (NASDAQ: LMAT) in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 5,450 shares of the medical instruments supplier's stock, valued at approximately $477,000. A number of

Shares of LeMaitre Vascular, Inc. (NASDAQ: LMAT - Get Free Report) have been assigned an average rating of "Hold" from the seven brokerages that are currently covering the firm, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average

After reaching an important support level, LeMaitre Vascular, Inc. (LMAT) could be a good stock pick from a technical perspective. LMAT recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.

LeMaitre Vascular delivered strong Q4 and FY 2025 results, with 16% YoY sales growth and broad-based margin expansion. Artegraft's international rollout exceeded expectations, with 2025 sales doubling guidance and a projected $10M in 2026. This could drive earnings growth for years to come. LMAT maintains a robust $190M net cash position and recently increased its dividend by 25%. The board has also authorized a $100M share repurchase program.